DK3067355T3 - Krystaller af diazabicyclooctanderivat og fremgangsmåde til fremstilling af krystaller af diazabicyclooctanderivat - Google Patents

Krystaller af diazabicyclooctanderivat og fremgangsmåde til fremstilling af krystaller af diazabicyclooctanderivat Download PDF

Info

Publication number
DK3067355T3
DK3067355T3 DK14852849.0T DK14852849T DK3067355T3 DK 3067355 T3 DK3067355 T3 DK 3067355T3 DK 14852849 T DK14852849 T DK 14852849T DK 3067355 T3 DK3067355 T3 DK 3067355T3
Authority
DK
Denmark
Prior art keywords
diazabicyclooctan
crystals
derivatives
manufacture
diazabicyclooctan derivatives
Prior art date
Application number
DK14852849.0T
Other languages
English (en)
Inventor
Takao Abe
Takeshi Furuuchi
Yoshiaki Sakamaki
Nakako Mitsuhashi
Yumiko Saito
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Application granted granted Critical
Publication of DK3067355T3 publication Critical patent/DK3067355T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DK14852849.0T 2013-10-08 2014-10-08 Krystaller af diazabicyclooctanderivat og fremgangsmåde til fremstilling af krystaller af diazabicyclooctanderivat DK3067355T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013211242 2013-10-08
PCT/JP2014/076875 WO2015053297A1 (ja) 2013-10-08 2014-10-08 ジアザビシクロオクタン誘導体の結晶とその製造法

Publications (1)

Publication Number Publication Date
DK3067355T3 true DK3067355T3 (da) 2021-01-04

Family

ID=52813113

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14852849.0T DK3067355T3 (da) 2013-10-08 2014-10-08 Krystaller af diazabicyclooctanderivat og fremgangsmåde til fremstilling af krystaller af diazabicyclooctanderivat

Country Status (21)

Country Link
US (4) US10131665B2 (da)
EP (4) EP3613740A1 (da)
JP (3) JP6617029B2 (da)
KR (2) KR102388529B1 (da)
CN (2) CN111153903A (da)
AR (1) AR097971A1 (da)
AU (1) AU2014332960B2 (da)
BR (2) BR122022016622B1 (da)
CA (2) CA2926071C (da)
DK (1) DK3067355T3 (da)
ES (2) ES2842225T3 (da)
HK (2) HK1219479A1 (da)
HU (1) HUE051925T2 (da)
IL (2) IL244969B (da)
MX (1) MX361659B (da)
NZ (5) NZ743374A (da)
RU (1) RU2695219C2 (da)
SG (1) SG11201602723RA (da)
TW (1) TWI673269B (da)
WO (1) WO2015053297A1 (da)
ZA (1) ZA201602054B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX366948B (es) 2012-05-30 2019-07-30 Meiji Seika Pharma Co Ltd Nuevo inhibidor de beta-lactamasa y proceso para prepararlo.
HUE049027T2 (hu) 2013-09-24 2020-08-28 Meiji Seika Pharma Co Ltd Diazabiciklooktán-származékok és intermedierek elõállítási eljárása
JP6617029B2 (ja) 2013-10-08 2019-12-04 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ジアザビシクロオクタン誘導体の結晶とその製造法
US10294224B2 (en) * 2014-12-05 2019-05-21 Meiji Seika Pharma Co., Ltd. Lyophilized composition of a diazabicyclooctane compound and process of producing the same
US10208041B2 (en) * 2016-10-07 2019-02-19 Hoffman-La Roche Inc. Diazabicyclooctane compounds
MA49623A (fr) 2017-07-21 2021-03-17 Antabio Sas Composés chimiques
WO2019064065A1 (en) 2017-09-27 2019-04-04 F. Hoffmann-La Roche Ag PHARMACEUTICAL FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
CA3076959A1 (en) * 2017-09-27 2019-04-04 Fedora Pharmaceuticals Inc. Crystalline forms of diazabicyclooctane derivatives and production process thereof
TW201920174A (zh) 2017-09-27 2019-06-01 瑞士商羅氏大藥廠股份有限公司 二氮雜雙環辛烷衍生物之醫藥形式及其製法
CN107941944B (zh) * 2017-11-23 2020-09-15 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酸乙酯草酸盐的检测方法
CN107991404B (zh) * 2017-11-23 2021-01-08 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酰胺的检测方法
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
US11897844B2 (en) * 2018-09-21 2024-02-13 Api Corporation Method for producing amino acid derivatives
WO2022014396A1 (ja) * 2020-07-13 2022-01-20 日本碍子株式会社 精製方法
CN113552250A (zh) * 2021-06-30 2021-10-26 海南海灵化学制药有限公司 一种盐酸头孢唑兰的杂质检测方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5038509B1 (da) 1970-10-21 1975-12-10
JPS6019759B2 (ja) 1977-11-24 1985-05-17 イ−ライ・リリ−・アンド・カンパニ− 非経口投予用１１１１５１５２１３９１９９東京都中央区京橋２丁目３番１３号
GB1589317A (en) 1977-11-24 1981-05-13 Lilly Co Eli Freeze drying cephalothin sodium
JPS60255723A (ja) 1984-05-31 1985-12-17 Ono Pharmaceut Co Ltd メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法
JPH07117533B2 (ja) 1985-08-28 1995-12-18 株式会社生体科学研究所 トランスフエリンおよびその用途
US20030220521A1 (en) 1989-07-27 2003-11-27 G.D. Searle & Co. Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
TW264475B (da) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
JP2843444B2 (ja) 1994-05-02 1999-01-06 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の結晶，該結晶を含む凍結乾燥製剤，およびその製造方法
AU700545B2 (en) 1994-05-02 1999-01-07 Shionogi & Co., Ltd. Crystal of pyrrolidylthiocarbapenem derivative, lyophilized preparation containing said crystal, and process for producing the same
DE19531874C1 (de) 1995-08-30 1996-10-02 Daimler Benz Ag Seitenwandbaugruppe für eine Kraftfahrzeugkarosserie
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
UA101966C2 (en) 2008-01-18 2013-05-27 Мерк Шарп Енд Доме Корп. Beta-lactamase inhibitors
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
WO2010126820A2 (en) * 2009-04-30 2010-11-04 Merck Sharp & Dohme Corp. Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
JP2012122603A (ja) 2010-11-15 2012-06-28 Nifco Inc コネクタ装置
CN103328476B (zh) 2010-12-22 2016-12-28 明治制果药业株式会社 光学活性二氮杂环辛烷衍生物及其制备方法
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
RU2769076C2 (ru) 2011-06-17 2022-03-28 Пфайзер Анти-Инфективз Аб Способ получения гетероциклических соединений, включая транс-7-оксо-6-(сульфокси)-1,6-диазабицикло[3.2.1]октан-2-карбоксамид и его соли
JP5666743B2 (ja) 2011-08-27 2015-02-12 ウォックハート リミテッド １，６−ジアザビシクロ［３，２，１］オクタン−７−オン誘導体および細菌感染の処置におけるそれらの使用
WO2013030735A1 (en) 2011-08-30 2013-03-07 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections
AU2012310136B2 (en) 2011-09-13 2016-07-07 Wockhardt Limited Nitrogen containing compounds and their use
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
MX366948B (es) 2012-05-30 2019-07-30 Meiji Seika Pharma Co Ltd Nuevo inhibidor de beta-lactamasa y proceso para prepararlo.
CA2881169C (en) * 2012-08-25 2020-06-16 Wockhardt Limited 1,6-diazabicyclo [3,2,1]octan - 7 - one derivatives and their use in the treatment of bacterial infections
HUE049027T2 (hu) * 2013-09-24 2020-08-28 Meiji Seika Pharma Co Ltd Diazabiciklooktán-származékok és intermedierek elõállítási eljárása
JP6617029B2 (ja) 2013-10-08 2019-12-04 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ジアザビシクロオクタン誘導体の結晶とその製造法
US10294224B2 (en) 2014-12-05 2019-05-21 Meiji Seika Pharma Co., Ltd. Lyophilized composition of a diazabicyclooctane compound and process of producing the same

Also Published As

Publication number Publication date
ES2901198T3 (es) 2022-03-21
MX361659B (es) 2018-12-13
BR112016006266A2 (da) 2017-08-22
NZ757222A (en) 2021-12-24
EP3067355A4 (en) 2017-04-26
KR102388529B1 (ko) 2022-04-20
TW201605855A (zh) 2016-02-16
NZ719568A (en) 2018-06-29
JP7182677B2 (ja) 2022-12-02
IL244969B (en) 2022-01-01
ZA201602054B (en) 2019-06-26
CA3110803A1 (en) 2015-04-16
JP6995810B2 (ja) 2022-01-17
NZ743374A (en) 2021-12-24
AU2014332960B2 (en) 2018-03-29
CA2926071C (en) 2021-11-09
US20160272641A1 (en) 2016-09-22
CA2926071A1 (en) 2015-04-16
US10131665B2 (en) 2018-11-20
EP3299370A1 (en) 2018-03-28
NZ757221A (en) 2021-12-24
KR102487297B1 (ko) 2023-01-12
JPWO2015053297A1 (ja) 2017-03-09
EP3613741A1 (en) 2020-02-26
CN111153903A (zh) 2020-05-15
KR20220054694A (ko) 2022-05-03
ES2842225T3 (es) 2021-07-13
BR122022016622B1 (pt) 2023-11-07
HK1250030A1 (zh) 2018-11-23
EP3299370B1 (en) 2021-11-24
RU2695219C2 (ru) 2019-07-22
JP6617029B2 (ja) 2019-12-04
WO2015053297A1 (ja) 2015-04-16
IL244969A0 (en) 2016-05-31
US11414417B2 (en) 2022-08-16
EP3067355A1 (en) 2016-09-14
RU2019115119A3 (da) 2022-04-26
CN105612159A (zh) 2016-05-25
KR20160065871A (ko) 2016-06-09
US10604522B2 (en) 2020-03-31
RU2019115119A (ru) 2019-05-29
US20190031659A1 (en) 2019-01-31
TWI673269B (zh) 2019-10-01
JP2020007366A (ja) 2020-01-16
IL289275B2 (en) 2023-02-01
AR097971A1 (es) 2016-04-20
HK1219479A1 (zh) 2017-04-07
JP2021193107A (ja) 2021-12-23
HUE051925T2 (hu) 2021-04-28
EP3613740A1 (en) 2020-02-26
CA3110803C (en) 2022-09-27
RU2016116501A3 (da) 2018-07-12
AU2014332960A1 (en) 2016-05-26
IL289275B (en) 2022-10-01
NZ757220A (en) 2021-12-24
RU2016116501A (ru) 2017-11-15
US20220348578A1 (en) 2022-11-03
MX2016004506A (es) 2016-06-16
SG11201602723RA (en) 2016-05-30
IL289275A (en) 2022-02-01
US20200181143A1 (en) 2020-06-11
BR112016006266B1 (pt) 2022-11-16
EP3067355B1 (en) 2020-12-16

Similar Documents

Publication Publication Date Title
DK3067355T3 (da) Krystaller af diazabicyclooctanderivat og fremgangsmåde til fremstilling af krystaller af diazabicyclooctanderivat
DK3019200T3 (da) Oligonukleotid-ligand-konjugater og fremgangsmåde til fremstiling deraf
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
DK2961831T3 (da) Sammensætninger og fremgangsmåder til immunterapi
DK3554121T3 (da) Konfiguration af fremgangsmåde til måling af mobilitetshåndtering
DK2958588T3 (da) Kombination af vaccination og hæmning af PD-1-reaktionsvejen
DK3003699T3 (da) Fodtøjsgenstand og fremgangsmåden til dannelse af genstanden
DK3009021T3 (da) Handske og fremgangsmåde til fremstilling deraf
DK3556869T3 (da) Sammensætninger og fremgangsmåder til sekventering af polynukleotider
DK3520912T3 (da) Fremgangsmåde og system til at forhindre begroning af overflader
DK3087095T3 (da) FcRn-antagonist og fremgangsmåder til anvendelse
DK2970872T3 (da) Mikroorganismer og fremgangsmåder til fremstilling af sialylerede og N-acetylglucosamin-holdige oligosaccharider
DK3071215T3 (da) Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension
DK3050883T3 (da) Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
DK3086807T3 (da) Antistoffer og fremgangsmåder til anvendelse
DK3068776T3 (da) Inhibitorer af replikation af influenzavira
DK3363805T3 (da) Fremgangsmåder til syntese af sphingomyeliner og dihydrosphingomyeliner
DK3007695T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK2981541T3 (da) Syntese og anvendelse af isotopmærkede glycaner
DK3082902T3 (da) Kropsbåret injektor og anvendelsesmetode
DK3078724T6 (da) Fremgangsmåde til fremstilling af biodiesel og relaterede produkter
DK3012255T3 (da) Stabil krystalform af tipiracilhydrochlorid og krystalliseringsfremgangsmåde dertil
DK2988756T4 (da) Formulering af kontraststof og dertil knyttet fremstillingsfremgangsmåde
DK3080353T3 (da) Fremgangsmåde til oprensning og isolering af lignin
DK3022361T4 (da) Rambuk og fremgangsmåde til anvendelse deraf